Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Dietary duo: fiber and Time-Restricted eating may cut cancer risk

NCT ID NCT07219706

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times

Summary

This study looks at whether eating more fiber and limiting when you eat can lower signs of cancer risk. Researchers will enroll 90 adults with obesity who currently eat little fiber. Participants will follow different diet plans to see how these changes affect weight, blood pressure, and inflammation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 90 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ≥18 age * Body mass index ≥30 kg/m2 * Dietary fiber intake ≤15 g/day * Compatible cell phone for use of ecological momentary assessment app Exclusion Criteria: * Self-reported diagnosis that precludes fiber intake (e.g., inflammatory bowel disease) * Food allergies or intolerances that limit ability to engage with the intervention * Positive screen on the SCOFF eating disorder screener39 * Current self-reported use of GLP-1 receptor agonists * Currently pregnant or breastfeeding, or planning to become pregnant

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer prevention are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Fasting Feeding Behavior Intermittent Fasting Weight Loss cancer prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Oklahoma Health Sciences

    Columbus, Ohio, 43230, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.